GlassScriptPhysician profile
Kevin Warren
NPI 1710516067
$3,837.06
in general payments reported to CMS, 2019-2025
9 companies · $2,178 in 2025
The $2,178 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $360 · 2024: $1,300 · 2025: $2,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297 · Travel and Lodging: $1,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,297.27 |
| Travel and Lodging | $1,539.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $1,761.98 | 2023-2025 | Advantagerib, Sternalock Blu System, Ribfix Titan |
| Biotissue Holdings INC. | $683.88 | 2024 | |
| Trimed, INC. | $617.50 | 2025 | |
| Atricure, INC. | $326.75 | 2025 | Atricure Cryoice Cryoablation System (Cryo2), Atricure Cryoice Cryosphere Cryoablation System |
| Davol INC. | $174.60 | 2024 | Phasix Mesh |
| Smith+Nephew, INC. | $124.80 | 2025 | Versajet, Collagenase Santyl, Oasis |
| Kci USA, INC. | $99.60 | 2023 | Prevena, V.A.C. Veraflo Cleanse Choice, Abthera Advance |
| Endo USA, INC. | $28.12 | 2025 | Xiaflex |
| Access Pro Medical, LLC | $19.83 | 2025 | Matriderm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.